SCHEMBL2761561

SCHEMBL2761561

CCOC(=O)CNC(=O)c1c(O)c2cc(Cl)cc(-c3cc(C(F)(F)F)nn3C)c2oc1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.38
HPGD P15428 2/20 0.37
ALDH1A1 P00352 4/20 0.35
GLA P06280 1/20 0.35
PKM P14618 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
MAPT P10636 1/20 0.34
STIM1 Q13586 1/20 0.34
ORAI1 Q96D31 1/20 0.34
EGLN2 Q96KS0 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2761892 0.90 EGLN1 (0.47) EGLN1STIM1ORAI1EGLN2L3MBTL1
SCHEMBL2472709 0.86 STIM1 (0.37) EGLN1HPGDALDH1A1GLAPKM
SCHEMBL2761937 0.80 ALDH1A1 (0.44) HPGDALDH1A1GLAPKMSMN1; SMN2
SCHEMBL2781241 0.79 ALDH1A1 (0.44) HPGDALDH1A1GLAPKMSMN1; SMN2
SCHEMBL2761588 0.77 EGLN1 (0.44) EGLN1EGLN2EGLN3
SCHEMBL2470821 0.76 EGLN1 (0.45) EGLN1ALDH1A1STIM1ORAI1EGLN2
SCHEMBL4345184 0.72 STIM1 (0.35) ALDH1A1STIM1ORAI1EGLN2HDAC3
SCHEMBL2473839 0.71 EGLN1 (0.43) EGLN1ALDH1A1STIM1ORAI1EGLN2
SCHEMBL2761908 0.67 HIF1A (0.44) EGLN1HIF1A
SCHEMBL2761973 0.67 HIF1A (0.43) ALDH1A1MAPTKDM4EHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 EGLN1 5/4885HPGD 37/4885ALDH1A1 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.